GET DAILY SIGNALSUnitedHealth (UNH) Shows Steady Turnaround Progress in Q3 2026 Earnings
Key Takeaways
- UnitedHealth reported third quarter 2026 revenue of $112.7 billion, slightly lower than a year ago but ahead of the $111.31 billion consensus estimate.
- Adjusted earnings per share (EPS) came in at $4.69, beating the roughly $4.14 Wall Street estimate and rising sharply from $2.92 a year earlier.
- The medical care ratio (MCR), the share of premiums spent on patient care, improved to 88.4% from 89.9%, reflecting stronger cost controls.
- Full-year 2026 adjusted EPS guidance was raised to at least $20.50, the third upward revision of the year.
- Shares rose in early trading as the results reinforced progress in the company's multi-year operational turnaround.
Why These Results Matter
UnitedHealth Group is the largest U.S. health insurer and a bellwether for the broader managed care sector. Its quarterly results carry outsized weight because they signal trends in medical costs, Medicare Advantage profitability, and pharmacy benefit management that ripple across peers. This report matters especially after a difficult 2025, when elevated medical expenses and weakness in the Optum Health business sent shares down sharply. Investors have since watched for evidence that pricing discipline, benefit design changes, and portfolio exits are restoring margins. The third quarter offered a key test of whether that recovery is durable heading into 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Showed
UnitedHealth posted third quarter 2026 revenue of $112.7 billion, down 0.4% year over year but above the $111.31 billion consensus. Adjusted EPS was $4.69, surpassing the roughly $4.14 analysts expected and up from $2.92 a year earlier. On a generally accepted accounting principles (GAAP) basis, diluted EPS was $4.56, compared with $2.59 in the prior-year quarter, while net income rose to about $4.11 billion from $2.35 billion.
The closely watched MCR improved to 88.4% from 89.9%, better than the roughly 89.7% forecast. Operating margin widened to 5.8% from 3.8%. The insurance arm, UnitedHealthcare, generated revenue of $86.3 billion and served 48.3 million people, while Optum revenue declined about 3% to roughly $66.9 billion, largely reflecting a deliberate pullback in lower-margin value-based care markets.
Management raised full-year 2026 adjusted EPS guidance to at least $20.50, up from a prior range of $19.50 to $20.00.
How the Market Responded
Shares rose in early trading following the release, advancing roughly 2% to 4% in premarket activity and pulling peers such as Humana and CVS Health higher. The market read the beat on both EPS and revenue, combined with a better-than-expected MCR, as confirmation that cost management efforts are working. Analysts described the quarter as another strong step in the turnaround, highlighting upside on medical costs and improved performance at Optum Health. Still, some caution persisted: executives noted that commercial medical trends remain elevated and that Medicaid margins continue to face pressure, tempering optimism about the pace of further improvement.
What to Watch Next
Investors will now focus on whether UnitedHealth can sustain its margin recovery through year-end and into 2027. The company's raised full-year guidance of at least $20.50 in adjusted EPS sets a higher bar, but management flagged expected investments in technology, artificial intelligence, and workflow improvements during the fourth quarter.
Medical cost trends remain the central swing factor. While the MCR improved year over year, executives cautioned that utilization is still elevated against historical norms, with specialty pharmaceuticals and arbitration awards tied to the No Surprises Act adding pressure in commercial plans.
Membership dynamics also warrant attention. Medicare Advantage enrollment has contracted as the company retools its portfolio for profitability, and Medicaid rolls continue to shrink amid ongoing eligibility redeterminations. Whether growth returns in 2027 will depend on positioning during the annual enrollment period.
Finally, watch balance sheet priorities, including progress toward a roughly 40% debt-to-capital ratio and continued share repurchases and dividends, which signal how confidently management views its cash generation.
Integrating AI Tools into My Research
When analyzing healthcare names like this, I often turn to Tickeron’s AI Screener to quickly filter for comparable stocks based on technical patterns, fundamentals, and AI-driven signals. It helps surface sector trends and potential opportunities without spending hours on manual screening, which keeps my process more efficient while I focus on the bigger picture.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UNH sees its Stochastic Oscillator ascends from oversold territory
On November 10, 2026, the Stochastic Oscillator for UNH moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 48 instances where the indicator left the oversold zone. In 33 of the 48 cases the stock moved higher in the following days. This puts the odds of a move higher at over 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
UNH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UNH crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +2.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 186 of 330 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 106 of 245 cases where UNH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 43%.
Bearish Trend Analysis
The 10-day RSI Indicator for UNH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 20 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 60 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 28 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
UNH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of hospital and medical service plans
Industry ManagedHealthCare
Advertisement